Evidence map›Paper›PMID 28770285›Full record

ReviewDer Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete2017

[Treatment of mycosis fungoides and Sézary syndrome].

J P Nicolay, C Assaf

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. [Current therapeutic options in Mycosis fungoides and Sézary syndrome].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2022
    Review
  2. Article
  3. Review
  4. [Cutaneous lymphomas : Clinical presentation - diagnosis - treatment].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

J P NicolayKlinik für Dermatologie, Venerologie und Allergologie, Medizinische Fakultät Mannheim, Ruprecht-Karls-Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68135, Mannheim, Deutschland. jan.nicolay@umm.de.
C AssafKlinik für Dermatologie und Venerologie, HELIOS Klinikum Krefeld, Krefeld, Deutschland.
Heidelberg University · DEHelios Klinikum Krefeld · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adequate therapeutic management of cutaneous T-cell lymphoma (CTCL) requires the identification of the exact CTCL stage and entity within the current WHO classification. There is no curative therapy for CTCL yet, so that treatment currently aims at improving symptoms and quality of life as well as reducing relapse rates. The treatment has to be stage-adapted. Therapeutic options comprise skin-directed as well as systemic treatment. In early stages, phototherapy and local steroids are the first-line therapeutic options. For the therapy of higher stages, interferon alpha and the RXR-specific retinoid bexarotene are used as first-line medications. Second-line treatment comprises monochemotherapy with agents like gemcitabine or liposomal doxorubicine. Nevertheless, the high relapse rates in higher stages make novel alternative treatment options necessary. As future therapy, especially the fusion protein brentuximab-vedotin directed against CD30 shows promising potential in clinical studies.

Indexed as

Adrenal Cortex HormonesBexaroteneBrentuximab VedotinDeoxycytidineDoxorubicinGemcitabineHumansImmunoconjugatesInterferon-alphaMycosis FungoidesNeoplasm Recurrence, LocalNeoplasm StagingPhototherapyPolyethylene GlycolsPUVA TherapySezary SyndromeAdrenal Cortex HormonesBexaroteneBrentuximab VedotinDeoxycytidineDoxorubicinGemcitabineImmunoconjugatesInterferon-alphaliposomal doxorubicinPolyethylene GlycolsCutaneous T-cell lymphomaQuality of lifeRecurrenceSystemic therapyWHO classification

Identifiers

PMID28770285
OpenAlexW2740108761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.